The reporter learned that Baiyu Pharmaceuticals signed an exclusive licensing agreement with Novartis for a small molecule anti-tumor drug. According to the agreement, Baiyu will receive a down payment of 70 million US dollars, as well as various milestone payments and corresponding royalties of up to 1.1 billion US dollars in development, registration and commercialization. Novartis will obtain exclusive global development and commercialization rights for this innovative small-molecule drug.

The reporter learned that Baiyu Pharmaceuticals signed an exclusive licensing agreement with Novartis for a small molecule anti-tumor drug. According to the agreement, Baiyu will receive a down payment of 70 million US dollars, as well as various milestone payments and corresponding royalties of up to 1.1 billion US dollars in development, registration and commercialization. Novartis will obtain exclusive global development and commercialization rights for this innovative small-molecule drug.